Appointed
John Dal Poggetto
Controller
SNOA ·
Sonoma Pharmaceuticals, Inc.
Effective July 17, 2023, our Board of Directors appointed John Dal Poggetto as our Controller.
Ready 8-Ks
34
Latest filing
April 30, 2026, 7:59 PM ET
Top materiality
0.75
Event mix
other_material ×21 · other ×7 · leadership ×4
Sentiment
6 pos · 3 neg · 25 neu
Executive change
recent →
Recent 8-K filings for SNOA
Highest-materiality recent filing
Sonoma Pharmaceuticals enters manufacturing supply agreement with Kenvue for Microcyn products in US
- Agreement with Kenvue Brands LLC for US sale of Microcyn-based products, effective Oct 24, 2025 through March 2027.
- Term includes two optional one-year renewals upon mutual written agreement.
-
Sonoma Pharmaceuticals prices $4.0M public offering of units at $1.35/unit
Offering of 2,962,962 units initially, each unit one share (or pre-funded warrant) and one warrant at $1.35 per unit.
-
Sonoma Pharmaceuticals enters manufacturing supply agreement with Kenvue for Microcyn products in US
Agreement with Kenvue Brands LLC for US sale of Microcyn-based products, effective Oct 24, 2025 through March 2027.
-
Sonoma Pharma terminates EVP/COO Bruce Thornton for cause, effective Oct 18
Bruce Thornton terminated as EVP and Chief Operating Officer on October 18, 2025.
-
Sonoma inks exclusive US distribution deal with WellSpring for Microcyn products
Exclusive US distribution agreement with WellSpring Pharmaceutical, effective Jan 29, 2025.
-
Sonoma Pharmaceuticals terminates exclusive supply agreement with EMC Pharma
EMC Pharma failed to meet minimum purchase quantities; 30-day cure period expired.
-
Sonoma expands Medline distribution to Canada and OTC retail in US and Canada
Amendment No. 1 to Distribution Agreement with Medline dated Oct 17, 2024 adds Canada and OTC wound care sales to retailers.
-
Authorized shares increased from 24M to 50M; reverse split ratio 1:20 effective Aug 29, 2024 at 5pm EDT.
-
Sonoma Pharmaceuticals enters 5-year distribution agreement with Medline for wound care products
Distribution agreement effective August 19, 2024, covers wound cleansers and other products in the United States.
-
Sonoma Pharma receives Nasdaq delisting notice for bid price non-compliance; say-on-pay vote fails
Received Nasdaq notice on Sept 22, 2023 for failure to maintain $1 minimum bid price for 30 consecutive days.
Executive changes
Materiality & sentiment trend
Max materiality 0.75 · Median 0.35 · Most common event other_material